Literature DB >> 11076666

Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer.

M R Hamblin1, M Del Governatore, I Rizvi, T Hasan.   

Abstract

Optimizing photodynamic therapy involves attempting to increase both the absolute tumour content of photosensitizer and the selectivity between tumour and surrounding normal tissue. One reason why photodynamic therapy has not been considered suitable for treatment of metastatic tumours in the liver, is the poor selectivity of conventional photosensitizers for tumour compared to normal liver. This report details an alternative approach to increasing this selectivity by the use of antibody-targeted photosensitizers (or photoimmunoconjugates) to target intrahepatic tumours caused by human colorectal cancer cells in the nude mouse, and explores the role of molecular charge on the tumour-targeting efficiency of macromolecules. The murine monoclonal antibody 17.1A (which recognizes an antigen expressed on HT 29 cells) was used to prepare site-specific photoimmunoconjugates with the photosensitizer chlorine6. The conjugates had either a predominant cationic or anionic charge and were injected i.v. into tumour-bearing mice. Biodistribution 3 or 24 h later was measured by extraction of tissue samples and quantitation of chlorine6 content by fluorescence spectroscopy. The photoimmunoconjugates were compared to the polylysine conjugates in an attempt to define the effect of molecular charge as well as antibody targeting. The anionic 17.1A conjugate delivered more than twice as much photosensitizer to the tumour at 3 h than other species (5 times more than the cationic 17. 1A conjugate) and had a tumour:normal liver ratio of 2.5. Tumour-to-liver ratios were greater than one for most compounds at 3 h but declined at 24 h. Tumour-to-skin ratios were high (> 38) for all conjugates but not for free chlorine6. Cationic species had a high uptake in the lungs compared to anionic species. The photoimmunoconjugates show an advantage over literature reports of other photosensitizers, which can result in tumour:normal liver ratios of less than 1. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076666      PMCID: PMC2363424          DOI: 10.1054/bjoc.2000.1486

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  The nature of the chromophore responsible for naturally occurring fluorescence in mouse skin.

Authors:  G Weagle; P E Paterson; J Kennedy; R Pottier
Journal:  J Photochem Photobiol B       Date:  1988-11       Impact factor: 6.252

2.  Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.

Authors:  N Sato; T Saga; H Sakahara; Z Yao; Y Nakamoto; M Zhang; M Kuroki; Y Matsuoka; Y Iida; J Konishi
Journal:  J Nucl Med       Date:  1999-04       Impact factor: 10.057

3.  Preferential binding of radiolabeled poly-L-lysines to C6 and U87 MG glioblastomas compared with endothelial cells in vitro.

Authors:  S E Kornguth; T Kalinke; H I Robins; J D Cohen; P Turski
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

4.  New method of photosensitizer accumulation for photodynamic therapy in an experimental liver tumor.

Authors:  Y Nishiwaki; S Nakamura; S Sakaguchi
Journal:  Lasers Surg Med       Date:  1989       Impact factor: 4.025

Review 5.  Resection of hepatic metastases from colorectal cancer. Biologic perspective.

Authors:  G Steele; T S Ravikumar
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

6.  Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates.

Authors:  D Mew; C K Wat; G H Towers; J G Levy
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

7.  Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose.

Authors:  S Duewell; W Horst; G Westera
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Mouse skin photosensitivity with dihaematoporphyrin ether (DHE) and aluminium sulphonated phthalocyanine (AlSPc): a comparative study.

Authors:  C J Tralau; A R Young; N P Walker; D I Vernon; A J MacRobert; S B Brown; S G Bown
Journal:  Photochem Photobiol       Date:  1989-03       Impact factor: 3.421

9.  The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies.

Authors:  H G Göttlinger; I Funke; J P Johnson; J M Gokel; G Riethmüller
Journal:  Int J Cancer       Date:  1986-07-15       Impact factor: 7.396

10.  Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin e6 immunoconjugates.

Authors:  M Del Governatore; M R Hamblin; E E Piccinini; G Ugolini; T Hasan
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  14 in total

Review 1.  Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.

Authors:  Girgis Obaid; Mans Broekgaarden; Anne-Laure Bulin; Huang-Chiao Huang; Jerrin Kuriakose; Joyce Liu; Tayyaba Hasan
Journal:  Nanoscale       Date:  2016-06-20       Impact factor: 7.790

2.  Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.

Authors:  Florencia Anatelli; Pawel Mroz; Qingde Liu; Changming Yang; Ana P Castano; Emilia Swietlik; Michael R Hamblin
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

3.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

4.  Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state.

Authors:  Q Liu; M R Hamblin
Journal:  Int J Immunopathol Pharmacol       Date:  2005 Jul-Sep       Impact factor: 3.219

Review 5.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

Review 6.  Application of photodynamic therapy for liver malignancies.

Authors:  Heng Zou; Fusheng Wang; Jiang-Jiao Zhou; Xi Liu; Qing He; Cong Wang; Yan-Wen Zheng; Yu Wen; Li Xiong
Journal:  J Gastrointest Oncol       Date:  2020-04

Review 7.  Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy.

Authors:  Tyler G St Denis; Michael R Hamblin
Journal:  Bioanalysis       Date:  2013-05       Impact factor: 2.681

Review 8.  Interstitial photodynamic laser therapy in interventional oncology.

Authors:  Thomas J Vogl; Katrin Eichler; Martin G Mack; Stephan Zangos; Christopher Herzog; Axel Thalhammer; Kerstin Engelmann
Journal:  Eur Radiol       Date:  2004-03-26       Impact factor: 5.315

9.  Targeting of T/Tn antigens with a plant lectin to kill human leukemia cells by photochemotherapy.

Authors:  Guillaume Poiroux; Marguerite Pitié; Raphaël Culerrier; Elodie Lafont; Bruno Ségui; Els J M Van Damme; Willy J Peumans; Jean Bernadou; Thierry Levade; Pierre Rougé; Annick Barre; Hervé Benoist
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates.

Authors:  M Carcenac; M Dorvillius; V Garambois; F Glaussel; C Larroque; R Langlois; N E Hynes; J E van Lier; A Pèlegrin
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.